Skip to main content

Table 2 Bivariate analysis of sociodemographic and SARS-CoV-2-specific variables between participants regarding their medication pausing status prior to or after first SARS-CoV-2 immunization, school education levels based on secondary education

From: Who is pausing immunosuppressive medication for COVID-19 vaccination? Results of an exploratory observational trial

 

Therapy paused (N = 59) n (%)

Therapy continued (N = 148) (%)

p-value

Gender

 Male

10 (17.5)

50 (34.0)

0.0261

 Female

47 (82.5)

97 (66.0)

Age, years

 Mean (sd)

52.3 (11.1)

51.8 (14.8)

0.7693

  < 40

9 (15.3)

35 (23.8)

0.0192

 40–65

45 (76.3)

82 (55.8)

 > 65

5 (8.5)

30 (20.4)

School education

 Lower

6 (10.7)

10 (7.1)

0.6892

 Middle

15 (26.8)

44 (31.2)

 Upper

36 (62.5)

85 (60.3)

 Other

0 (0)

2 (1.4)

Previous COVID-19 infection

 Yes

1 (1.7)

2 (1.4)

11

First administered vaccine

 BNT162b2 (Pfizer/BioNTech)

36 (65.5)

95 (68.3)

0.8282

 AZD 1222 (AstraZeneca)

12 (21.8)

30 (21.8)

 mRNA-1,273 (Moderna)

7 (12.7)

14 (10.1)

 Good Subjective Health statusa

28 (47.5)

93 (62.8)

0.0601

 Good Quality of Lifea

32 (54.2)

92 (62.2)

0.3461

 PHQ-4D > 5

9 (15.0)

22 (15.3)

11

  1. Data are n (%) or mean (SD)
  2. aRated on a 7-point Likert-scale where participants with the highest three ratings are categorized
  3. 1Fisher’s exact test
  4. 2Fisher–Freeman–Halton exact test
  5. 3Welch’s t-test, bold p-values < 0.05